ANALOGUES OF HYDROXYCHLOROQUINE (HCQ) WITHOUT RETINAL TOXICITY
申请人:Inoviem Scientific
公开号:US20190062278A1
公开(公告)日:2019-02-28
The present invention relates to hydroxychloroquine analogues having an activity superior to that of hydroxychloroquine but free from retinal cytotoxicity of formula (I), their pharmaceutically acceptable salts, solvates or hydrates:
their method of preparation and their use in the treatment of lupus erythematosus.
Analogues of hydroxychloroquine (HCQ) without retinal toxicity
申请人:Inoviem Scientific
公开号:US10647677B2
公开(公告)日:2020-05-12
The present invention relates to hydroxychloroquine analogues having an activity superior to that of hydroxychloroquine but free from retinal cytotoxicity of formula (I), their pharmaceutically acceptable salts, solvates or hydrates:
their method of preparation and their use in the treatment of lupus erythematosus.
Potent antiviral activity of novel multi-substituted 4-anilinoquin(az)olines
作者:Sirle Saul、Szu-Yuan Pu、William J. Zuercher、Shirit Einav、Christopher R.M. Asquith
DOI:10.1016/j.bmcl.2020.127284
日期:2020.8
Screening a series of 4-anilinoquinolines and 4-anilinoquinazolines enabled identification of potent novel inhibitors of dengue virus (DENV). Preparation of focused 4-anilinoquinoline/quinazoline scaffold arrays led to the identification of a series of high potency 6-substituted bromine and iodine derivatives. The most potent compound 6-iodo-4-((3,4,5-trimethoxyphenyl)amino)quinoline-3-carbonitrile (47) inhibited DENV infection with an EC50 = 79 nM. Crucially, these compounds showed very limited toxicity with CC(50 )values > 10 mu M in almost all cases. This new promising series provides an anchor point for further development to optimize compound properties.
ANALOGUES DE L'HYDROXYCHLOROQUINE (HCQ) DEPOURVUS DE TOXICITE RETINIENNE
申请人:Inoviem Scientific
公开号:EP3303295A2
公开(公告)日:2018-04-11
[EN] ANALOGUES OF HYDROXYCHLOROQUINE (HCQ) WITHOUT RETINAL TOXICITY<br/>[FR] ANALOGUES DE L'HYDROXYCHLOROQUINE (HCQ) DEPOURVUS DE TOXICITE RETINIENNE
申请人:INOVIEM SCIENT
公开号:WO2016193503A2
公开(公告)日:2016-12-08
La présente invention concerne des analogues de I'hydroxychloroquine présentant une activité supérieure à I'hydroxychloroquine mais dépourvu de cytotoxicité rétinienne de formule (I), leurs sels, solvates ou hydrates pharmaceutiquement acceptables : leur procédé de préparation et leur utilisation dans le traitement du lupus érythémateux.